CL2017003208A1 - Unidad de dosificación orodispersable que contiene un componente estetrol - Google Patents

Unidad de dosificación orodispersable que contiene un componente estetrol

Info

Publication number
CL2017003208A1
CL2017003208A1 CL2017003208A CL2017003208A CL2017003208A1 CL 2017003208 A1 CL2017003208 A1 CL 2017003208A1 CL 2017003208 A CL2017003208 A CL 2017003208A CL 2017003208 A CL2017003208 A CL 2017003208A CL 2017003208 A1 CL2017003208 A1 CL 2017003208A1
Authority
CL
Chile
Prior art keywords
stetrol
weight
solid dosage
dosage unit
dosing unit
Prior art date
Application number
CL2017003208A
Other languages
English (en)
Inventor
Severine Francine Isabella Jaspart
Johannes Jan Platteeuw
Den Heuvel Denny Johan Ma Van
Original Assignee
Mithra Pharmaceuticals S A
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mithra Pharmaceuticals S A filed Critical Mithra Pharmaceuticals S A
Publication of CL2017003208A1 publication Critical patent/CL2017003208A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/18—Feminine contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/30—Oestrogens

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Endocrinology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Reproductive Health (AREA)
  • Diabetes (AREA)
  • Inorganic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

<p>LA INVENCIÓN PROPORCIONA UNA UNIDAD DE DOSIFICACIÓN SÓLIDA ORO-DISPERSABLE FARMACÉUTICA QUE TIENE UN PESO COMPRENDIDO ENTRE 30 Y 1000 MG, CONSISTIENDO DICHA UNIDAD DE DOSIFICACIÓN EN: (A) 0,1-25% EN PESO DE PARTÍCULAS DE ESTETROL QUE CONTIENEN AL MENOS 80% EN PESO DE UN COMPONENTE ESTETROL SELECCIONADO ENTRE ESTETROL, ÉSTERES DE ESTETROL Y COMBINACIONES DE LOS MISMOS; Y (B) 75-99,9% EN PESO DE UNO O MÁS INGREDIENTES FARMACÉUTICAMENTE ACEPTABLES; COMPRENDIENDO LA UNIDAD DE DOSIFICACIÓN SÓLIDA QUE AL MENOS 100 UG DEL COMPONENTE ESTETROL; Y EN LA QUE LA UNIDAD DE DOSIFICACIÓN SÓLIDA SE PUEDE OBTENER MEDIANTE UN PROCEDIMIENTO QUE COMPRENDE LA COMPRESIÓN DE UNA MEZCLA SECA DE PARTÍCULAS DE ESTETROL Y UNO O MÁS EXCIPIENTES  FARMACÉUTICAMENTE ACEPTABLES EN UNA UNIDAD DE DOSIFICACIÓN SÓLIDA. LA UNIDAD DE DOSIFICACIÓN SÓLIDA ES FÁCIL DE FABRICAR Y PERFECTAMENTE ADECUADA PARA SU ADMINISTRACIÓN SUBLINGUAL, BUCAL O SUBLABIAL.</p>
CL2017003208A 2015-06-18 2017-12-14 Unidad de dosificación orodispersable que contiene un componente estetrol CL2017003208A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP15172747 2015-06-18

Publications (1)

Publication Number Publication Date
CL2017003208A1 true CL2017003208A1 (es) 2018-04-13

Family

ID=53442623

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2017003208A CL2017003208A1 (es) 2015-06-18 2017-12-14 Unidad de dosificación orodispersable que contiene un componente estetrol

Country Status (43)

Country Link
US (3) US20160367567A1 (es)
EP (1) EP3106148B1 (es)
JP (1) JP6863547B2 (es)
KR (1) KR102664563B1 (es)
CN (2) CN107771075A (es)
AU (1) AU2016280863B2 (es)
CA (1) CA2988498C (es)
CL (1) CL2017003208A1 (es)
CO (1) CO2017012766A2 (es)
CR (1) CR20180042A (es)
CU (1) CU24523B1 (es)
CY (1) CY1120467T1 (es)
DK (1) DK3106148T3 (es)
DO (1) DOP2017000293A (es)
EA (1) EA035651B1 (es)
EC (1) ECSP17085669A (es)
ES (1) ES2671160T3 (es)
GE (2) GEP20217308B (es)
GT (1) GT201700270A (es)
HK (1) HK1251940A1 (es)
HR (1) HRP20180889T1 (es)
HU (1) HUE037383T2 (es)
IL (1) IL256283B (es)
LT (1) LT3106148T (es)
MX (1) MX385820B (es)
MY (1) MY195019A (es)
NO (1) NO3106148T3 (es)
NZ (1) NZ737948A (es)
PE (1) PE20180398A1 (es)
PH (1) PH12017502325B1 (es)
PL (1) PL3106148T3 (es)
PT (1) PT3106148T (es)
RS (1) RS57328B1 (es)
SA (1) SA517390550B1 (es)
SG (1) SG10202010432UA (es)
SI (1) SI3106148T1 (es)
SM (1) SMT201800232T1 (es)
SV (1) SV2017005595A (es)
TN (1) TN2017000499A1 (es)
TR (1) TR201808438T4 (es)
UA (1) UA123098C2 (es)
WO (1) WO2016203011A1 (es)
ZA (1) ZA201708287B (es)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RS54880B1 (sr) 2011-06-01 2016-10-31 Estetra Sprl Postupak proizvodnje intermedijarnih proizvoda estetrola
ME02585B (me) 2011-06-01 2017-06-20 Estetra Sprl Postupak proizvodnje intermedijara estetrola
EP2383279A1 (en) 2011-07-19 2011-11-02 Pantarhei Bioscience B.V. Process for the preparation of estetrol
CU24523B1 (es) 2015-06-18 2021-06-08 Estetra Sprl Unidad de dosificación orodispersable que contiene un componente estetrol
LT3310345T (lt) * 2015-06-18 2021-06-25 Estetra Sprl Burnoje disperguojama tabletė, turinti estetrolio
MA44206B1 (fr) 2015-06-18 2021-04-30 Estetra Sprl Comprimé orodispersible comprenant estetrol
EP3701944B1 (en) 2015-06-18 2021-12-08 Estetra SRL Orodispersible dosage unit containing an estetrol component
CA3178291A1 (en) 2016-08-05 2018-04-12 Estetra Srl Method for the management of dysmenorrhea and menstrual pain
TWI801561B (zh) * 2018-04-19 2023-05-11 比利時商依思特拉私人有限責任公司 化合物及其用於緩解絕經相關症狀的用途
EP3781171B1 (en) * 2018-04-19 2022-02-09 Estetra SRL Compounds and their uses for alleviating menopause-associated symptoms
TWI893101B (zh) 2020-04-16 2025-08-11 比利時商埃斯特拉有限責任公司 具有降低之副作用之避孕組成物
AU2021351921A1 (en) 2020-09-29 2023-04-06 Millicent Pharma Limited Orodispersible formulations
JP2024543177A (ja) * 2021-11-29 2024-11-19 エステトラ エスアールエル 毛の成長を促進するための組成物

Family Cites Families (121)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3138588A (en) 1962-08-24 1964-06-23 American Home Prod 17-ketals of estrone and derivatives thereof
US3433785A (en) 1966-07-11 1969-03-18 Sterling Drug Inc 15,16-disubstituted aromatic steroids,intermediates and processes
US4826831A (en) 1983-08-05 1989-05-02 Pre Jay Holdings Limited Method of hormonal treatment for menopausal or post-menopausal disorders involving continuous administration of progestogens and estrogens
CA1306950C (en) 1987-04-10 1992-09-01 Alec D. Keith Buccal administration of estrogens
US5073374A (en) 1988-11-30 1991-12-17 Schering Corporation Fast dissolving buccal tablet
GB2228412B (en) 1989-02-28 1993-04-14 Syntex Inc Nicardipine pharmaceutical composition for parenteral administration
US5340586A (en) 1991-04-12 1994-08-23 University Of Southern California Methods and formulations for use in treating oophorectomized women
US5340585A (en) 1991-04-12 1994-08-23 University Of Southern California Method and formulations for use in treating benign gynecological disorders
US5895783A (en) 1993-07-16 1999-04-20 Schering Aktiengesellschaft Treatment of preeclampsia and preterm labor with combination of progestational agent and a nitric oxide synthase substrate and/or donor
JPH07101977A (ja) 1993-10-05 1995-04-18 Kureha Chem Ind Co Ltd ホルモン作用を軽減した新規なエストラジオール誘導体及びその増殖因子阻害剤
DE4344405C2 (de) 1993-12-24 1995-12-07 Marika Dr Med Ehrlich Ovulationshemmendes Mittel und Verfahren zur hormonalen Kontrazeption
WO1997004752A1 (en) 1995-07-26 1997-02-13 Duramed Pharmaceuticals, Inc. Pharmaceutical compositions of conjugated estrogens and methods for their use
FR2772272B1 (fr) 1997-12-16 2000-01-14 Rhone Poulenc Rorer Sa Compositions pharmaceutiques a base de dalfopristine et de quinupristine et leur preparation
JP2001526212A (ja) 1997-12-19 2001-12-18 スミスクライン・ビーチャム・コーポレイション 咀嚼分散性錠剤の製造法
US7815937B2 (en) 1998-10-27 2010-10-19 Biovail Laboratories International Srl Quick dissolve compositions and tablets based thereon
US6117446A (en) * 1999-01-26 2000-09-12 Place; Virgil A. Drug dosage unit for buccal administration of steroidal active agents
US6180682B1 (en) * 1999-01-26 2001-01-30 Virgil A. Place Buccal drug delivery system for use in male contraception
TW548277B (en) 1999-07-16 2003-08-21 Akzo Nobel Nv Orally active androgens
IL149424A (en) 1999-12-02 2007-05-15 Organon Nv Androgens are converted to methylene at positions 15,14
US20020132801A1 (en) 2001-01-11 2002-09-19 Schering Aktiengesellschaft Drospirenone for hormone replacement therapy
FR2809619B1 (fr) 2000-06-06 2004-09-24 Pharmatop Nouvelles formulations aqueuses de principes actifs sensibles a l'oxydation et leur procede d'obtention
EP1216713A1 (en) 2000-12-20 2002-06-26 Schering Aktiengesellschaft Compositions of estrogen-cyclodextrin complexes
DE60217324T2 (de) 2001-05-18 2007-04-26 Pantarhei Bioscience B.V. Pharmazeutische zusammensetzung für die hormonersatztherapie
EP1260225A1 (en) 2001-05-18 2002-11-27 Pantarhei Bioscience B.V. A pharmaceutical composition for use in hormone replacement therapy
US20020193356A1 (en) 2001-05-23 2002-12-19 Van Beek Agatha Antonia Magdalena Means and method for hormonal contraception
DK1390042T3 (da) 2001-05-23 2008-03-31 Pantarhei Bioscience Bv System for administration af et lægemiddel omfattende tetrahydroxyleret östrogen til anvendelse i hormonal svangerskabsforebyggelse
DE60234515D1 (de) 2001-05-23 2010-01-07 Pantarhei Bioscience Bv Tetrahydroxylierte estrogen enthaltendes arzneistoffverabreichungssystem zur verwendung in hormonalen kontrazeption
DE60101276T2 (de) * 2001-05-23 2004-04-22 Pantarhei Bioscience B.V. Zubereitungen für die hormonale Kontrazeption
WO2003018026A1 (en) 2001-08-31 2003-03-06 Pantarhei Bioscience B.V. Use of estrogenic compounds in combination with progestogenic compounds in hormone-replacement therapy
DE60216630T2 (de) * 2001-11-15 2007-09-20 Pantarhei Bioscience B.V. Verwendung von östrogen in kombination mit progestogen für die hormonsubstitutiionstherapie
US6723348B2 (en) 2001-11-16 2004-04-20 Ethypharm Orodispersible tablets containing fexofenadine
HU227198B1 (en) 2001-11-27 2010-10-28 Richter Gedeon Nyrt Pharmaceutical composition for emergency contraception containing levonorgestrel
JP5037779B2 (ja) 2002-02-21 2012-10-03 バイエル ファーマ アクチエンゲゼルシャフト １又は複数のステロイド、１又は複数のテトラヒドロ葉酸成分およびビタミンｂ１２を含む医薬組成物
US20050147670A1 (en) 2002-05-29 2005-07-07 Impax Laboratories Inc. Oral disintegrating dosage forms
ES2399423T3 (es) 2002-06-11 2013-04-01 Pantarhei Bioscience B.V. Método para tratar la piel humana y una composición para el cuidado de la piel para su uso en tal método
SI1511496T1 (sl) 2002-06-11 2007-04-30 Pantarhei Bioscience Bv Metoda zdravljenja ali prevencije imunsko mediiranih motenj in farmacevtska formulacija za njeno uporabo
EP1526856B1 (en) 2002-07-12 2008-01-02 Pantarhei Bioscience B.V. Pharmaceutical composition comprising estetrol derivatives for use in cancer therapy
KR20050059092A (ko) 2002-08-28 2005-06-17 로버트 캐스퍼 에스트로겐 보충 요법
WO2004037269A1 (en) 2002-10-23 2004-05-06 Pantarhei Bioscience B.V. Pharmaceutical compositions comprising estetrol derivatives for use in cancer therapy
WO2004041289A1 (en) 2002-11-05 2004-05-21 Schering Aktiengesellschaft Cardiovascular protection using anti-aldosteronic progestins
CN100343269C (zh) 2002-11-08 2007-10-17 潘塔希生物科学股份有限公司 通过雌酮衍生的甾体化合物合成雌四醇
PL1624878T3 (pl) 2003-05-22 2007-01-31 Pantarhei Bioscience Bv Zastosowanie kompozycji zawierającej estrogenowy składnik w celu leczenia i zapobiegania bólowi mięśniowo-szkieletowemu
ES2482104T3 (es) 2003-09-29 2014-08-01 Novo Nordisk Femcare Ag Formulaciones HRT
ES2933479T3 (es) 2003-09-29 2023-02-09 Novo Nordisk Healthcare Ag Estabilidad mejorada de formulaciones de progestágenos
JP3841804B2 (ja) 2003-10-15 2006-11-08 富士化学工業株式会社 口腔内速崩壊性錠剤用の組成物
EP1535618A1 (en) 2003-11-26 2005-06-01 Schering Aktiengesellschaft Pharmaceutical preparation for continuous hormonal treatment over a period of longer than 21-28 days comprising two estrogen and/or progestin compositions
MY151322A (en) 2004-04-30 2014-05-15 Bayer Ip Gmbh Management of breakthrough bleeding in extended hormonal contraceptive regimens
GB0410616D0 (en) 2004-05-13 2004-06-16 Unilever Plc Antiperspirant or deodorant compositions
WO2005115349A1 (de) 2004-05-28 2005-12-08 Grünenthal GmbH Folsäurehaltiges kontrazeptivum
DE102004026670A1 (de) 2004-05-28 2005-12-15 Grünenthal GmbH Hormonales Kontrazeptivum enthaltend eine Kombination aus Ethinylestradiol und Chlormadinonacetat
EP1773292B1 (en) 2004-07-01 2009-03-11 LEK Pharmaceuticals D.D. Rapidly disintegrating orodispersible composition containing nonfilamentous coprocessed polyols particles and silicified microcrystalline cellulose
UA89964C2 (ru) 2004-09-08 2010-03-25 Н.В. Органон 15β-ЗАМЕЩЕННЫЕ СТЕРОИДЫ, КОТОРЫЕ ИМЕЮТ СЕЛЕКТИВНУЮ ЭСТРОГЕННУЮ АКТИВНОСТЬ
CA2644400C (en) 2005-02-03 2014-04-08 Nycomed Pharma As Fast wet-massing method for the preparation of calcium-containing compositions
IS7724A (is) 2005-03-02 2006-09-03 Actavis Group Samsetning á töflum með hraða sundrun sem innihalda þungt magnesíum karbónat
UY29527A1 (es) 2005-05-13 2006-12-29 Schering Ag Composicinn farmaccutica que contienen gestrgenos y/o estrngenos y 5-metil - (6s) - tetrhidrofolato.
CN102796160A (zh) 2005-05-26 2012-11-28 索尔瓦药物有限公司 17β-HSD1和STS抑制剂
US20070048369A1 (en) * 2005-08-26 2007-03-01 National Starch And Chemical Investment Holding Corporation Mucosal delivery tablet
ATE481973T1 (de) * 2006-01-09 2010-10-15 Pantarhei Bioscience Bv Verfahren zur behandlung einer akuten gefässerkrankung
US20090221540A1 (en) 2006-01-09 2009-09-03 Pantarhei Bioscience B.V. Method of Treating An Acute Vascular Disorder
MX2008011074A (es) 2006-03-02 2008-09-10 Warner Chilcott Co Inc Metodo anticonceptivo oral multifasico de ciclo prolongado.
US20070286819A1 (en) * 2006-06-08 2007-12-13 Warner Chilcott Company, Inc. Methods to administer ethinyl estradiol and prodrugs thereof with improved bioavailability
US20080113953A1 (en) 2006-06-08 2008-05-15 Warner Chilcott Company, Inc. Methods to administer solid dosage forms of ethinyl estradiol and prodrugs thereof with improved bioavailability
MX2008014941A (es) * 2006-06-08 2008-12-10 Warner Chilcott Co Inc Metodos para administrar formas de dosificacion solida de etinil estradiol y profarmacos del mismo con biodisponibilidad mejorada.
MX2009000256A (es) 2006-07-06 2009-02-18 Bayer Schering Pharma Ag Preparaciones farmaceuticas para la anticoncepcion y para prevenir el riesgo de malformaciones congenitas.
CN101489563A (zh) 2006-07-06 2009-07-22 拜耳先灵医药股份有限公司 用于避孕和预防先天性畸形风险的药物制剂
JP2010511062A (ja) 2006-11-29 2010-04-08 ワイス エルエルシー エストロゲン／ｓｅｒｍおよびエストロゲン／プロゲスチン二層錠剤
RU2465907C2 (ru) 2006-12-20 2012-11-10 Тева Вимен'С Хелс, Инк. Распадающиеся в полости рта твердые дозированные формы, содержащие прогестин, и способы получения и применение указанных дозированных форм
DE602008001783D1 (de) 2007-01-08 2010-08-26 Pantarhei Bioscience Bv Verfahren zur behandlung oder prävention von unfruchtbarkeit bei weiblichen säugern und pharmazeutisches kit zur anwendung dieses verfahrens
EP2117518A2 (en) 2007-01-12 2009-11-18 Wyeth a Corporation of the State of Delaware Tablet-in-tablet compositions
EP1972618A1 (en) 2007-03-20 2008-09-24 Nabriva Therapeutics AG Pleuromutilin derivatives for the treatment of diseases mediated by microbes
EP2155205B1 (en) 2007-06-21 2011-12-21 Pantarhei Bioscience B.V. Treatment of meconium aspiration syndrome with estrogens
CA2693982C (en) 2007-07-19 2017-03-14 Pantarhei Bioscience B.V. Treatment or prevention of hypertensive disorders of pregnancy or fetal growth retardation
FR2920311B1 (fr) 2007-08-31 2010-06-18 Galenix Innovations Composition solide, orodispersible et/ou dispersible, sans excipient a effet notoire et son procede de preparation
JP5399749B2 (ja) 2008-03-27 2014-01-29 沢井製薬株式会社 プロトンポンプ阻害剤を含有する被覆微粒子
US20110250274A1 (en) 2008-09-19 2011-10-13 Shaked Ze Ev Estriol formulations
CN101780073B (zh) 2009-01-21 2013-07-03 重庆圣华曦药业股份有限公司 非布司他分散片药物及其制备方法
US8303868B2 (en) 2009-01-26 2012-11-06 Shin-Etsu Chemical Co., Ltd. Wet granulation tableting method using aqueous dispersion of low-substituted hydroxypropyl cellulose
DE102009007771B4 (de) 2009-02-05 2012-02-16 Bayer Schering Pharma Aktiengesellschaft Bukkales Applikationssystem, 17α-Estradiol enthaltend
US20120077888A1 (en) 2009-03-26 2012-03-29 Royal College Of Surgeons In Ireland Orodispersible tablets
ITMI20091109A1 (it) 2009-06-23 2010-12-24 Wyeth Corp Forma polimorfa d di bazedoxifene acetato e metodi per la sua preparazione
CN102458386B (zh) 2009-06-23 2016-04-06 拜耳知识产权有限责任公司 用于紧急避孕的药物组合物
CN102058604A (zh) 2009-11-17 2011-05-18 北京万全阳光医学技术有限公司 一种含有地诺孕素和戊酸雌二醇的药物组合物及其制备方法
KR20130097073A (ko) 2010-04-15 2013-09-02 바이엘 인텔렉쳐 프로퍼티 게엠베하 초저-용량의 ｈｒｔ용 고체 경구 투여 형태
EP2399904A1 (en) 2010-05-26 2011-12-28 Nabriva Therapeutics AG Process for the preparation of pleuromutilins
US10849857B2 (en) 2010-07-28 2020-12-01 Laboratorios Leon Farma Sa Pharmaceutical compositions comprising active drugs, contraceptive kits comprising active drugs, and methods of administering the same
AR081670A1 (es) 2010-06-29 2012-10-10 Leon Farma Sa Lab Composicion farmaceutica que comprende drospirenona y kit anticonceptivo
US9603860B2 (en) 2010-07-28 2017-03-28 Laboratorios Leon Farma Sa Pharmaceutical compositions comprising active drugs, contraceptive kits comprising active drugs, and methods of administering the same
WO2012055840A1 (en) 2010-10-28 2012-05-03 Bayer Pharma Aktiengesellschaft Composition and preparation for treatment of dysmenorrhea and menstrual pain and use of a hormonal agent and a zinc salt for treatment of menstrual disorders
NZ611467A (en) 2010-12-02 2015-06-26 Aptalis Pharmatech Inc Rapidly dispersing granules, orally disintegrating tablets and methods
JP2012240917A (ja) 2011-05-16 2012-12-10 Zensei Yakuhin Kogyo Kk 製剤化用微粒子とそれを含む製剤
RS54880B1 (sr) 2011-06-01 2016-10-31 Estetra Sprl Postupak proizvodnje intermedijarnih proizvoda estetrola
ME02585B (me) 2011-06-01 2017-06-20 Estetra Sprl Postupak proizvodnje intermedijara estetrola
EP2383279A1 (en) 2011-07-19 2011-11-02 Pantarhei Bioscience B.V. Process for the preparation of estetrol
KR102033187B1 (ko) 2011-07-19 2019-10-16 판타레이 바이오사이언스 비.브이. 디하이드로에피안드로스테론(ｄｈｅａ)을 함유하는 정제
CA2843951C (en) 2011-08-11 2019-08-06 Wout WOUTERS Use of estetrol as emergency contraceptive
JP6174585B2 (ja) 2011-09-16 2017-08-02 フェリング ベスローテン フェンノートシャップ 速溶性医薬組成物
AU2012320423C1 (en) 2011-10-07 2018-01-25 Estetra Srl Process for the production of estetrol
WO2013090117A1 (en) 2011-12-13 2013-06-20 Arstat, Inc. A multiphasic contraceptive regimen for oral combination drug formulation of progestin and estrogen
US9808470B2 (en) 2012-04-19 2017-11-07 Universite De Liege Estrogenic components for use in the treatment of neurological disorders
EP2653163A1 (en) 2012-04-19 2013-10-23 Université de Liège Estrogenic components for use in the treatment of neurological disorders
US9238265B2 (en) 2012-09-27 2016-01-19 General Electric Company Backstrike protection during machining of cooling features
WO2014159377A1 (en) * 2013-03-14 2014-10-02 Teva Women's Health, Inc. Compositions containing tanaproget and natural estrogens
JP6126456B2 (ja) 2013-05-17 2017-05-10 東和薬品株式会社 打錠用顆粒とその製造方法、その打錠用顆粒を用いた口腔内崩壊錠
AU2014268779A1 (en) 2013-05-21 2016-01-21 Predictive Therapeutics, LLC Therapeutic and method of use
ES2624667T3 (es) 2013-09-18 2017-07-17 Crystal Pharma, S.A.U. Procedimiento para la preparación de estetrol
US12274276B2 (en) 2013-10-03 2025-04-15 Altria Client Services Llc Dissolvable-chewable tablet
DK3079671T3 (en) 2013-12-12 2017-12-11 Donesta Bioscience B V Orally disintegrating solid dosage unit containing an estetrol component
WO2016053946A1 (en) 2014-09-29 2016-04-07 The Regents Of The University Of California Compositions and methods for maintaining cognitive function
AU2016264137B2 (en) 2015-05-18 2021-08-19 Agile Therapeutics, Inc. Contraceptive compositions and methods for improved efficacy and modulation of side effects
MA44206B1 (fr) 2015-06-18 2021-04-30 Estetra Sprl Comprimé orodispersible comprenant estetrol
LT3310345T (lt) 2015-06-18 2021-06-25 Estetra Sprl Burnoje disperguojama tabletė, turinti estetrolio
EP3701944B1 (en) 2015-06-18 2021-12-08 Estetra SRL Orodispersible dosage unit containing an estetrol component
CU24523B1 (es) 2015-06-18 2021-06-08 Estetra Sprl Unidad de dosificación orodispersable que contiene un componente estetrol
JP6827962B2 (ja) 2015-06-23 2021-02-10 ラボラトリオス レオン ファーマ エスエー 過剰体重に影響される女性患者のためのドロスピレノン系避妊薬
KR102780201B1 (ko) 2016-10-28 2025-03-12 에스테트라, 소시에떼 아 레스폰서빌리떼 리미떼 월경통 및 생리통의 관리방법
US20200046729A1 (en) 2016-08-05 2020-02-13 Estetra Sprl Methods using combined oral contraceptive compositions with reduced cardiovascular effects
CA3178291A1 (en) 2016-08-05 2018-04-12 Estetra Srl Method for the management of dysmenorrhea and menstrual pain
IL276584B2 (en) 2018-02-07 2024-10-01 Estetra Srl Contraceptive composition with reduced cardiovascular effects
EP3781171B1 (en) 2018-04-19 2022-02-09 Estetra SRL Compounds and their uses for alleviating menopause-associated symptoms
TWI801561B (zh) 2018-04-19 2023-05-11 比利時商依思特拉私人有限責任公司 化合物及其用於緩解絕經相關症狀的用途
TWI893101B (zh) 2020-04-16 2025-08-11 比利時商埃斯特拉有限責任公司 具有降低之副作用之避孕組成物

Also Published As

Publication number Publication date
PH12017502325A1 (en) 2018-06-25
US20160367567A1 (en) 2016-12-22
US20190125759A1 (en) 2019-05-02
RS57328B1 (sr) 2018-08-31
CY1120467T1 (el) 2019-07-10
US10660903B2 (en) 2020-05-26
GEAP202114677A (en) 2021-06-10
KR20180021085A (ko) 2018-02-28
NO3106148T3 (es) 2018-08-11
SA517390550B1 (ar) 2022-03-16
PH12017502325B1 (en) 2021-04-14
CU20170159A7 (es) 2018-07-05
HRP20180889T1 (hr) 2018-08-10
TR201808438T4 (tr) 2018-07-23
HUE037383T2 (hu) 2018-08-28
ES2671160T3 (es) 2018-06-05
SMT201800232T1 (it) 2018-07-17
JP2018517717A (ja) 2018-07-05
MY195019A (en) 2023-01-03
PT3106148T (pt) 2018-05-10
CU24523B1 (es) 2021-06-08
DOP2017000293A (es) 2018-01-31
KR102664563B1 (ko) 2024-05-09
AU2016280863B2 (en) 2021-04-01
LT3106148T (lt) 2018-06-25
US11957694B2 (en) 2024-04-16
TN2017000499A1 (en) 2019-04-12
SV2017005595A (es) 2018-09-10
CA2988498A1 (en) 2016-12-22
IL256283A (en) 2018-02-28
NZ737948A (en) 2023-03-31
CO2017012766A2 (es) 2018-03-28
EA035651B1 (ru) 2020-07-22
CN107771075A (zh) 2018-03-06
SG10202010432UA (en) 2020-11-27
ECSP17085669A (es) 2018-03-31
GT201700270A (es) 2019-08-30
EA201890084A1 (ru) 2018-05-31
PL3106148T3 (pl) 2018-08-31
MX385820B (es) 2025-03-18
JP6863547B2 (ja) 2021-04-21
UA123098C2 (uk) 2021-02-17
WO2016203011A1 (en) 2016-12-22
US20200352959A1 (en) 2020-11-12
GEP20217308B (en) 2021-10-25
CN116077454A (zh) 2023-05-09
PE20180398A1 (es) 2018-02-28
EP3106148B1 (en) 2018-03-14
EP3106148A1 (en) 2016-12-21
MX2017016276A (es) 2018-06-19
SI3106148T1 (en) 2018-08-31
CR20180042A (es) 2018-05-03
HK1251940A1 (zh) 2019-05-03
IL256283B (en) 2021-02-28
AU2016280863A1 (en) 2018-01-18
DK3106148T3 (en) 2018-05-07
CA2988498C (en) 2022-02-08
ZA201708287B (en) 2020-01-29

Similar Documents

Publication Publication Date Title
GT201700270A (es) Unidad de dosificación orodispersable que contiene un componente estetrol
CL2017003209A1 (es) Unidad de dosificación orodispersable que contiene un componente estetrol
AR134152A2 (es) Composiciones sólidas que comprenden un agonista del glp-1 y una sal del ácido n-(8-(2-hidroxibenzoil)amino)caprílico
CY1124052T1 (el) Δισκιο διασπειρομενο στο στομα περιεχον οιστετρολη
CY1124104T1 (el) Δισκιο διασπειρομενο στο στομα περιεχον οιστετρολη
AR111760A1 (es) Compuestos y composiciones para el tratamiento de tumores sólidos mediante administración intratumoral
EA201892778A1 (ru) Фармацевтическая композиция для перорального введения с улучшенной однородностью состава, содержащая пеллеты с замедленным высвобождением, содержащие тамсулозина гидрохлорид
CL2024000429A1 (es) Contra enfermedades inflamatorias intestinales que involucra la disrupción del ensamblaje de heterómeros ccr9:drd5
EA202091127A1 (ru) Фармацевтические композиции, включающие сафинамид
EA201800226A1 (ru) Фармацевтическая композиция, обладающая анксиолитическим и снотворным действием
CO2019013645A2 (es) Dropropizina en combinación con ambroxol en la forma farmacéutica de jarabe y tabletas
DOP2019000190A (es) Composición de liberación rápida de cinitaprida y simeticona y proceso para prepararla.
UA123399U (uk) Фармацевтична композиція холіну альфосцерату у лікарській формі для орального застосування